Operations Research Center, Massachusetts Institute of Technology, Cambridge.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
JAMA Surg. 2022 Aug 1;157(8):e221819. doi: 10.1001/jamasurg.2022.1819. Epub 2022 Aug 10.
In patients with resectable colorectal cancer liver metastases (CRLM), the choice of surgical technique and resection margin are the only variables that are under the surgeon's direct control and may influence oncologic outcomes. There is currently no consensus on the optimal margin width.
To determine the optimal margin width in CRLM by using artificial intelligence-based techniques developed by the Massachusetts Institute of Technology and to assess whether optimal margin width should be individualized based on patient characteristics.
DESIGN, SETTING, AND PARTICIPANTS: The internal cohort of the study included patients who underwent curative-intent surgery for KRAS-variant CRLM between January 1, 2000, and December 31, 2017, at Johns Hopkins Hospital, Baltimore, Maryland, Memorial Sloan Kettering Cancer Center, New York, New York, and Charité-University of Berlin, Berlin, Germany. Patients from institutions in France, Norway, the US, Austria, Argentina, and Japan were retrospectively identified from institutional databases and formed the external cohort of the study. Data were analyzed from April 15, 2019, to November 11, 2021.
Hepatectomy.
Patients with KRAS-variant CRLM who underwent surgery between 2000 and 2017 at 3 tertiary centers formed the internal cohort (training and testing). In the training cohort, an artificial intelligence-based technique called optimal policy trees (OPTs) was used by building on random forest (RF) predictive models to infer the margin width associated with the maximal decrease in death probability for a given patient (ie, optimal margin width). The RF component was validated by calculating its area under the curve (AUC) in the testing cohort, whereas the OPT component was validated by a game theory-based approach called Shapley additive explanations (SHAP). Patients from international institutions formed an external validation cohort, and a new RF model was trained to externally validate the OPT-based optimal margin values.
This cohort study included a total of 1843 patients (internal cohort, 965; external cohort, 878). The internal cohort included 386 patients (median [IQR] age, 58.3 [49.0-68.7] years; 200 men [51.8%]) with KRAS-variant tumors. The AUC of the RF counterfactual model was 0.76 in both the internal training and testing cohorts, which is the highest ever reported. The recommended optimal margin widths for patient subgroups A, B, C, and D were 6, 7, 12, and 7 mm, respectively. The SHAP analysis largely confirmed this by suggesting 6 to 7 mm for subgroup A, 7 mm for subgroup B, 7 to 8 mm for subgroup C, and 7 mm for subgroup D. The external cohort included 375 patients (median [IQR] age, 61.0 [53.0-70.0] years; 218 men [58.1%]) with KRAS-variant tumors. The new RF model had an AUC of 0.78, which allowed for a reliable external validation of the OPT-based optimal margin. The external validation was successful as it confirmed the association of the optimal margin width of 7 mm with a considerable prolongation of survival in the external cohort.
This cohort study used artificial intelligence-based methodologies to provide a possible resolution to the long-standing debate on optimal margin width in CRLM.
在可切除结直肠癌肝转移(CRLM)患者中,手术技术和切除边缘的选择是唯一受外科医生直接控制并可能影响肿瘤学结果的变量。目前对于最佳切缘宽度尚无共识。
利用麻省理工学院开发的基于人工智能的技术确定 CRLM 的最佳切缘宽度,并评估最佳切缘宽度是否应根据患者特征进行个体化。
设计、设置和参与者:该研究的内部队列纳入了 2000 年 1 月 1 日至 2017 年 12 月 31 日期间在马里兰州巴尔的摩的约翰霍普金斯医院、纽约的纪念斯隆凯特琳癌症中心和德国柏林的 Charité-柏林大学医学院接受根治性手术治疗 KRAS 变异型 CRLM 的患者。来自法国、挪威、美国、奥地利、阿根廷和日本机构的患者从机构数据库中回顾性确定,并形成了该研究的外部队列。数据分析于 2019 年 4 月 15 日至 2021 年 11 月 11 日进行。
肝切除术。
在 2000 年至 2017 年期间在 3 个三级中心接受手术的 KRAS 变异型 CRLM 患者形成了内部队列(训练和测试)。在训练队列中,一种名为最优策略树(OPTs)的基于人工智能的技术通过构建随机森林(RF)预测模型来推断与给定患者死亡概率最大降低相关的边缘宽度(即最优边缘宽度)。通过计算其在测试队列中的曲线下面积(AUC)验证了 RF 成分,而 OPT 成分则通过称为 Shapley 加法解释(SHAP)的博弈论方法进行验证。国际机构的患者形成了外部验证队列,并训练了一个新的 RF 模型来对外验证基于 OPT 的最优边缘值。
这项队列研究共纳入了 1843 名患者(内部队列 965 名;外部队列 878 名)。内部队列包括 386 名(中位数[IQR]年龄,58.3[49.0-68.7]岁;200 名男性[51.8%])患有 KRAS 变异型肿瘤的患者。RF 反事实模型在内部训练和测试队列中的 AUC 均为 0.76,这是迄今为止报道的最高值。患者亚组 A、B、C 和 D 的推荐最优边缘宽度分别为 6、7、12 和 7mm。SHAP 分析在很大程度上证实了这一点,建议亚组 A 为 6 至 7mm,亚组 B 为 7mm,亚组 C 为 7 至 8mm,亚组 D 为 7mm。外部队列包括 375 名(中位数[IQR]年龄,61.0[53.0-70.0]岁;218 名男性[58.1%])患有 KRAS 变异型肿瘤的患者。新的 RF 模型的 AUC 为 0.78,这使得对基于 OPT 的最优边缘的外部验证成为可能。外部验证是成功的,因为它证实了 7mm 的最优边缘宽度与外部队列中生存时间的显著延长有关。
这项队列研究使用基于人工智能的方法,为 CRLM 中最佳切缘宽度的长期争论提供了一个可能的解决方案。